Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial is a research paper published in Open Forum Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 AI124214
National Institutes of Health
Grant: T32 DK072922 and TL1 DK132771
National Institutes of Health
Grant: UL1TR003015
National Institutes of Health
Grant: KL2TR003016
Medical Research Council UK
Grant: MR/V011235/1
Myeloid cells in type 2 immunity: unravelling susceptibility and resistance to tissue nematode infection
Wellcome Trust
Grant: 106898/A/15/Z
Wellcome Trust
Grant: unidentified
unidentified
National Institutes of Health
Grant: 3UL1TR003015-03S1
The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve Health
National Institutes of Health
Grant: 2R01AI124214-06
Role of Type 2 Immunity in Innate Protection from C. difficile
Wellcome Trust
Grant: 106898
Chitinase-like proteins: Host protection through molecular multi-tasking.
National Institutes of Health
Grant: 3T32DK072922-08S1
Kidney Disease and Inflammation
National Institutes of Health
Grant: 1KL2TR003016-01
Institutional Career Development Core
National Institutes of Health
Grant: 5TL1DK132771-05
IGNITE KUH NRSA Training Core
Keywords
Sustainable Development Goals